Background Recent studies have questioned the safety of drug-eluting stents because of a higher incidence of late stent thrombosis, raising the possibility that drug-eluting stents may be associated with an increased mortality. The effect of drug-eluting stents on mortality in AfricanAmericans is unknown.
Introduction
First-generation drug-eluting stents (DES) have been shown to reduce the incidence of in-stent restenosis (ISR) [1] . Since the initial publication in 2002 in highly selected patients and lesions [1] , the use of DES has expanded rapidly and is being used in a majority of percutaneous coronary interventions (PCI) [2] . Recent studies have, however, questioned the safety of DES because of a possible higher incidence of late stent thrombosis and death in patients receiving DES compared with bare metal stents (BMS) [3] [4] [5] .
African-Americans have been shown to have more comorbidities and tend to present at a younger age for PCI compared with Caucasians [6] . Although in-hospital outcomes have been reported to be similar in AfricanAmericans, post-PCI an increased 1-year mortality in African-Americans compared with Caucasians has been published [6] [7] [8] . The impact of DES on long-term mortality in African-Americans is unknown. The purpose of this study is to determine the long-term mortality in African-Americans treated with DES in an inner city single-center institution.
Methods

Study cohort
This is a retrospective analysis of 628 consecutive African-American patients from our bolus-only platelet glycoprotein IIb/IIIa inhibitor (GPI) database. We retrospectively analyzed 1293 (1001 consecutive patients during January 2003-August 2004 and 292 consecutive patients during December 2004-August 2005 in two separate studies [9, 10] ) patients who underwent PCI with a GPI bolus-only regimen. We included all AfricanAmericans in this study from this database. The first PCI occurring during this time period is taken as the index procedure. Patients who underwent PCI with either BMS or DES were included. Patients who underwent balloon angioplasty alone or who had both BMS and DES implanted were excluded from the study. Patients without a valid social security number were excluded from the study because longer-term follow-up was obtained using the social security death index. The University Hospital of Brooklyn's Institutional Review Board approved the study. Demographic, periprocedural, and laboratory data were collected by reviewing charts and hospital records. The in-hospital events and the length of stay were also recorded. Patients with ST-segment elevation myocardial infarction (STEMI) were not treated with a bolus-only GPI and were, therefore, excluded from the database.
Periprocedural medication
All patients were loaded with aspirin 325 mg and clopidogrel 300-600 mg before PCI. All patients received an initial bolus of intravenous 40 units/kg unfractionated heparin and a bolus of GPI (0.25 mg/kg abciximab, 25 mg/kg tirofiban or 180 mg/kg Â 2 eptifibatide) at the beginning of the intervention which is the standard practice at our institution [9, 10] . If necessary, supplemental boluses of unfractionated heparin were administered to achieve a target activated clotting time of at least 200 s. Activated clotting time was measured using the Hemochron (ITC Technidyne Corp., Edison, New Jersey, USA) device.
Coronary intervention
Coronary interventional procedures were performed according to standard techniques, via a femoral approach. The choice of DES versus BMS was dependent on the operator's discretion. DES was, however, preferred in patients with diabetes and long lesions in distal narrow caliber vessels. BMS were preferred in nondiabetics especially with proximal large caliber vessels. Femoral vascular closure devices (Angio-Seal, St. Jude Medical, Minnetonka, Minnesota, USA) or Perclose (Perclose Inc., Redwood City, California, USA) were used, unless contraindicated. Cardiac biomarkers were measured every 8 h for 24 h after PCI and hemoglobin levels were measured every 24 h until the patient was discharged. At the time of discharge all patients were advised to take aspirin indefinitely. Patients treated with DES were recommended to take clopidogrel for at least 9-12 months and patients treated with BMS were recommended to take clopidogrel for at least 1 month after the procedure.
Follow-up
We used all-cause mortality as our long-term outcome. The social security death index [11] was used to determine the time of death on 31 August 2007.
Definitions
Left ventricular dysfunction was defined, as all patients with left ventricular ejection fraction less than 50%.
Post-PCI myocardial infarction (MI) was defined according to the Thrombolysis in Myocardial Infarction criteria [12] . A new MI was defined by biochemical or electrocardiographic criteria: the MB isoform of creatinine kinase (CK-MB) at least three times the upper limit of the normal range in at least one blood sample, or the finding of abnormal Q-waves in two or more contiguous leads. For patients with recent MI, who had an elevated CK-MB level before the procedure, a value of more than three times the upper limit of normal and at least 50% above the baseline value was required to meet the definition.
Bleeding was defined according to the Randomized Evaluation in the PCI Linking Angiomax to Reduced Clinical Events criteria [13] . Major bleeding was defined as either any intracranial, intraocular, or retroperitoneal, or clinically overt bleeding with a drop of hemoglobin by 3 g/dl, or any drop of hemoglobin by 4 g/dl, or the transfusion of two or more units of packed red blood cells. Minor bleeding was defined as clinically overt bleeding not meeting the above criteria.
Thrombocytopenia was defined as a fall in the platelet count below 100 000/ml, or a decrease by 25% below baseline values, in the event the initial platelet count was less than 100 000/ml.
Chronic kidney disease was defined as all patients with creatinine above 1.5 mg/dl including end-stage renal disease (ESRD). Patients were considered ESRD if they were dependent on chronic dialysis.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as percentages. w 2 test was used to compare the differences between categorical variables. The independent samples t-test was used to compare continuous variables with normal distribution and the Mann-Whitney test was used to compare continuous variables without a normal distribution. For the in-hospital outcomes, logistic regression analyses were conducted to assess the univariate effect of predictors of interest and the extent of confounding or interaction of these predictors with covariates statistically significant in univariate analysis. Event-free survival rates during the follow-up period were estimated by the Kaplan-Meier method and tested by the log-rank statistic. Multivariable Cox proportionalhazards regression modeling was used to estimate the independent effect of stent type (DES vs. BMS) in the study population. Sequential models were fit with the initial model including no covariates (unadjusted); the final model included covariates selected by stepwise methods which had a significant impact (P < 0.05) on all-cause mortality. P values of less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed utilizing SPSS software version 15.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics
The baseline characteristics are listed in Table 1 and procedural characteristics are presented in Table 2 . The mean age of the patients in the DES arm was younger compared with those who received BMS (61.9 vs. 62.8 years respectively, P = 0.37). The mean body mass index (BMI) of the patients included in the BMS arm (30.5 kg/m 2 ) was higher than the DES arm (29.6 kg/m 2 ; P = 0.05). The BMS arm had more patients with non-STEMI (NSTE-MI) compared with the DES arm (12.1% of DES vs. 18.2% of BMS arm; P = 0.041). More patients with diabetes mellitus received DES compared with BMS (53.7% of DES vs. 45.3% of BMS; P = 0.044). The predominantly used GPI in the DES arm was tirofiban (47.5%) followed by eptifibatide (35%). In the BMS arm, the predominantly used GPI was eptifibatide (50.4%) followed by abciximab (47.4%). More patients undergoing left anterior descending artery intervention received DES compared with BMS (46.6 vs. 32.5% respectively; P < 0.001). The mean length of the stent was longer in the DES arm (19.7 ± 7.1 mm in DES vs. 12.7 ± 4 mm in the BMS arm; P < 0.001) and the mean diameter of the stents used was wider in the BMS arm (3.3 ± 0.6 mm in BMS vs. 3.0 ± 0.4 mm in DES arm; P < 0.001).
In-hospital outcomes
The in-hospital outcomes are presented in Table 3 . No in-hospital deaths or repeat revascularization are observed. The incidence of post-PCI MI (3.4% in DES vs. 4.7 in BMS arm, P = 0.99) bleeding complications (1.7% in DES vs. 2.9% in BMS arm, P = 0.17) and thrombocytopenia (2% in DES arm vs. 1.1% in BMS arm, P = 0.16) were not significant between the two arms. In the logistic regression analysis, NSTEMI as an indication for PCI [P = 0.012; hazard ratio (HR) = 3.1; 95% confidence intervals (CI): 1.3-7.5] and mean diameter of the stent used (P = 0.04; HR = 2.4; 95% CI: 1.4-5.3) were strong predictors of in-hospital post-PCI MI.
All-cause mortality
During the follow-up period of 3 ± 0.9 years, the unadjusted mortality rate was 12.8% in the BMS arm versus 7.1% in the DES arm (P = 0.084) (Fig. 1) . After adjustment for covariates with significant impact on mortality, (Table 4 ) (BMI, chronic kidney disease, congestive heart failure, NSTEMI as an indication for PCI, percentage stenosis of the vessel and pre-PCI hemoglobin) there was no significant difference in mortality (P = 0.19; HR = 1.4; 95% CI: 0.8-2.4) at the end of the follow-up period. In a subgroup analyses, the mortality rate was not statistically significant between the two arms in the diabetic patients after adjustment for congestive heart failure, chronic kidney disease, and pre-PCI hemoglobin (14.5 vs. 9.5% in BMS and DES arms, respectively, unadjusted P = 0.43, adjusted P = 0.49; HR = 1.3; CI = 0.6-2.4) (Fig. 2) . In the patients who underwent PCI for acute coronary syndrome (ACS), the BMS arm had significantly higher mortality (17.1% in BMS arm vs. 6.3% in DES arm, unadjusted P value = 0.008, after adjustment for BMI and pre-PCI hemoglobin, P = 0.022; HR = 2.2; CI: 1.1-4.4) (Fig. 3) . In patients with chronic kidney disease, there was a significantly higher mortality in the BMS arm after adjustment for BMI and pre-PCI hemoglobin (36.7% in BMS arm vs. 20.4% in DES arm, unadjusted P = 0.18, adjusted P = 0.044; HR = 2.3; CI: 1.02-5.2) (Fig. 4) .
Discussion
Our study is the first to evaluate the safety of DES in an African-American population. Our results suggest that not only there is no increase in long-term all-cause Log-rank test P-value: 0.084
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Kaplan-Meier survival curves for bare metal stents (BMS) arm and drug-eluting stents (DES) arm in patients with acute coronary syndrome. At 3 ± 0.9 years, the mortality rate was 6.3% in the DES arm versus 17.1% in the BMS arm (P = 0.008 by log-rank test).
mortality after DES implantation, but there seems to be a numerically lower mortality rate in the overall population compared with BMS arm and a statistically significant lower mortality in the subgroups with ACS and chronic kidney disease.
Our finding that there is no significant impact of DES on long-term mortality is consistent with previously reported meta-analyses and a pooled analysis [14] [15] [16] [17] . More recent observational and registry studies on DES versus BMS, however, reported survival benefit with DES on longterm follow-up. Observational study by Groeneveld et al. [18] in Medicare beneficiaries, which included approximately 150 000 patients showed statistically significant survival benefit with DES compared with BMS. Furthermore, Tu et al. [19] showed that in the cardiac care network of Ontario's population-based clinical registry of all patients undergoing PCI in Ontario, there was a statistically significant survival benefit with DES compared with BMS. In our study, an unadjusted mortality trend was higher in the BMS arm but a significantly greater number of patients with NSTEMI received BMS and after adjustment for NSTEMI and other covariates with significant impact on all-cause mortality, there was no difference between the two arms. It is possible that the reduction in acute MI and death secondary to reduction in ISR by DES might have been offset by the minor increase in late stent thrombosis caused by DES. African-Americans have, however, been shown to have lower rates of target vessel revascularization [7] questioning the need for DES in the context of presumed increase in late stent thrombosis. This study suggests that in African-Americans, the use of DES seems to be noninferior to BMS in terms of long-term mortality. An interesting finding in our study was the improvement in survival with DES in patients presenting with an ACS and in patients with chronic kidney disease. No definitive evidence that DES improves long-term outcomes in patients with non-ST segment ACS is found, such as those included in our study. Kandzari et al. [22] reported that the use of DES in high-risk non-ST segment ACS patients was associated with a significant reduction in in-hospital death and cardiogenic shock. A meta-analysis [23] of seven randomized controlled trials on DES versus BMS in patients with acute myocardial infarction (AMI) showed that at a mean follow-up of 8-12 months there was a significant reduction in the need for target vessel revascularization (4.8% in DES vs. 12.0% of BMS), whereas the rates of death and MI were similar. It has been shown by Chen et al. [24] that 9.5% of ISR presented with MI and 26.7% of ISR presented as unstable angina requiring hospitalization. If DES significantly reduces in-hospital deaths and cardiogenic shock and reduces ISR over 8-12 months, significant reduction of all-cause mortality in the ACS subgroup by DES may be feasible.
In patients with chronic kidney disease, our results are in agreement with the study by Jeong et al. [25] who reported that DES is associated with a significant reduction in death at 1 year compared with BMS in patients. Furthermore, Halkin et al. [26] showed that there is a trend towards mortality benefit with DES in patients with ESRD requiring hemodialysis. In our subgroup analysis of all patients with creatinine above 1.5 mg including patients requiring hemodialysis, there seems to be a mortality benefit with DES.
The possible mechanisms for the improved survival with DES in certain subgroups are unknown. Intervention in patients with ACS have been shown to be a risk factor for ISR probably from vascular injury caused by PCI, worsening the persisting thrombogenic milieu and increasing cellular proliferation [27] . Similarly, patients with history of chronic kidney disease have also been shown to have higher rates of ISR [28] . Reduction in acute MI and death secondary to reduction in ISR by DES might have led to the observed lower mortality in these subgroups of patients [29, 30] .
Our study has a number of limitations. This study is a retrospective analysis and has all the inherent limitations of a retrospective study. The baseline and procedural characteristics between the two arms were reasonably similar, but there were certain differences which had to be adjusted. In particular, the DES arm seemed to contain a lower-risk patient population compared with the BMS group. Despite adjustment, there could be residual confounding variables that could lead to the observed differences in outcomes between the two arms. We excluded patients with STEMI. We included all-cause mortality as our end point and we excluded those patients without a valid social security number that might have introduced a selection bias. All-cause mortality is, however, considered the most unbiased endpoint in long-term outcomes studies, especially if they are retrospective, as other chronic medical conditions may affect the attributed cause of death [31, 32] . The rates of stent thrombosis and repeat revasularization in our study population are unknown, as long-term follow-up was obtained using social security death index and, therefore, restricted to unspecified mortality. We did not include the on-label versus off-label indications for the stents used in our study population. A recently reported study by Marroquin et al. [33] , however, showed that among the off-labeled use of BMS and DES, there was no significant difference in death/MI at 1 year.
Despite these limitations, we conclude that implantation of DES is not associated with an increased long-term mortality in African-Americans and may improve survival in ACS and chronic kidney disease subgroups. These observations would be best confirmed in large randomized controlled studies.
